From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer

TL;DR

This paper explores new treatment strategies for ovarian clear cell cancer, focusing on personalized medicine and novel therapies to improve patient outcomes.

Contribution

The paper highlights novel therapeutic approaches such as immune checkpoint blockade and ARID1A synthetic lethal interactions for ovarian clear-cell cancer.

Findings

Resistance to conventional chemotherapy is a major cause of poor prognosis in ovarian clear-cell cancer.

Fertility-sparing surgery is considered for early-stage patients who wish to have children.

Venous thromboembolism increases the risk of adverse events in these patients.

Abstract

Ovarian clear-cell cancer is a rare subtype of epithelial ovarian cancer with unique clinical and biological features. Despite optimal cytoreductive surgery and platinum-based chemotherapy being the standard of care, most patients experience drug resistance and a poor prognosis. Therefore, novel therapeutic approaches have been developed, including immune checkpoint blockade, angiogenesis-targeted therapy, ARID1A synthetic lethal interactions, targeting hepatocyte nuclear factor 1β, and ferroptosis. Refining predictive biomarkers can lead to more personalized medicine, identifying patients who would benefit from chemotherapy, targeted therapy, or immunotherapy. Collaboration between academic research groups is crucial for developing prognostic outcomes and conducting clinical trials to advance treatment for ovarian clear-cell cancer. Immediate progress is essential, and research efforts should prioritize the development of more effective therapeutic strategies to benefit all patients.

• Resistance to conventional chemotherapy is one of the main reasons for the worse prognosis of OCCC patients.

• FSS for OCCC patients with Stage IA and a strong desire to have children.

• VTE increases the risk of various adverse events in OCCC patients.

Figures